The sweet pill

If you had held onto Dr. Reddy's Laboratories for the last decade, you would have also held onto the stock through one-third of the company's lifetime that has seen the company turn revenues of around ₹2,000 crore (FY05) to ₹15,000 plus crore in FY15. That's sales compounding at an annual rate of 22.3 per cent. The lucrative market that the US is has helped Dr. Reddy's compound its operating profit at a faster annual rate of 37.2 per cent during this period. Shareholders are a happy lot too, making nine times their investment in the last decade. The US brings in around half of global generic revenues

This article was originally published on December 03, 2015.